
Johnson & Johnson Releases New Data from Phase III MARIPOSA Trial of Rybrevant-Lazcluze Combination in Non-Small Cell ...
Johnson & Johnson has shared new, positive data from the Phase III MARIPOSA clinical trial of Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal …